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Abstract In 1980, Dr. Michel Mirowski and his team
inserted the first implantable cardioverter defibrillator (ICD)
in a patient. Initially, ICD therapy was not widely accepted,
and many physicians actually considered this therapy
unethical. Large secondary and primary prevention trials,
demonstrating a beneficial effect of ICD therapy in selected
patients not only on arrhythmic death but also on all-cause
mortality, stimulated a rapid growth in the number of
implants and increased patient’s and physician’s acceptance.
Improvements in size and weight, arrhythmia discrimination
capabilities, battery technology, shock waveform and output,
monitoring capabilities and defibrillator electrode technology
eventually resulted in the current large number of yearly
implants. Today, almost 40 years after the conception of the
ICD and 25 years after the first human implant, ICD therapy
is the treatment of choice for patients at risk for life-
threatening arrhythmias either as secondary or primary
prevention. Furthermore, with the more recent addition of
resynchronisation therapy to standard ICD therapy, it became
possible to treat selected patients with advanced symptoms
of heart failure and to lower the risk of sudden death.




Sudden cardiac death, mainly caused by ventricular
arrhythmias (VA) in a population with coronary artery
disease, is a major cause of mortality in the Western world.
In the USA alone, the annual incidence of sudden cardiac
death varies from 200,000 to 450,000 of which most fatal
events occur outside the hospital [1]. Since the prevention
of these events has always been difficult, Mirowski and co-
workers developed the implantable cardioverter defibrillator
(ICD), and in 1980, the first ICD was implanted in a human
[2]. Initially, the ICD was thought to be a treatment of last
resort for the prevention of sudden cardiac death. Soon it
became clear that, if it were to be possible to identify
patients at risk, it would be the treatment of choice for
patients at high risk for life-threatening arrhythmias [3]. In
1984, 4 years after the first human implant, the first ICD
was implanted in the Netherlands at the University Medical
Center Utrecht.
The first ICDs were large (8×11.5 cm, 170 cm
3) and
heavy (280 g). These devices required open chest surgery,
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DOI 10.1007/s12471-010-0047-3and the device was implanted in the abdomen. Needless to
say, these procedures were associated with a high rate of
complications. Algorithms for the detection of potentially
life-threatening VA were limited, and the occurrence of
inappropriate device therapy was frequent. At that time,
ICD therapy was not generally accepted and considered
unethical and even inhuman by many. Despite the high
failure rate of drug therapy, many physicians preferred
treating their patients with antiarrhythmic drugs. Large
secondary and primary prevention trials demonstrating the
efficacy of ICD therapy were necessary to stimulate a wider
use and to increase patient’s acceptance.
Furthermore,first-generationdeviceswereratherbulky,and
many improvements in size and weight, arrhythmia discrim-
ination, battery technology, shock waveform and output,
monitoring capabilities, and defibrillator electrode technology
were necessary to allow the current large-scale yearly
implantations. However, the first human implants marked the
start ofanew way of treating patients at risk ofdying suddenly.
In other words, the era of ICD therapy had begun.
Secondary Prevention Trials
Initially, to be eligible for ICD treatment, patients had to
survive at least one episode of life-threatening VA such as
ventricular fibrillation (VF) or ventricular tachycardia (VT;
secondary prevention). In the 1990s, three large trials
proved the effectiveness of ICD therapy for the secondary
prevention of arrhythmic death: the Antiarrhythmics Versus
Implantable Defibrillator study (AVID) [4], the Canadian
Implantable Defibrillator Study (CIDS) [5] and the Cardiac
Arrest Study Hamburg (CASH; Table 1)[ 6]. The AVID
trial enrolled patients who had survived a cardiac arrest or
with documented sustained VAs. Patients were randomised
to either amiodarone therapy or ICD treatment, and the
primary endpoint was all-cause mortality. The results
showed a reduction in all-cause mortality of 28% in the
defibrillator group [4]. The CIDS trial had a similar design
and showed a 20% reduction in mortality in the ICD group,
compared with amiodarone treatment [5]. The CASH trial
enrolled patients who survived an episode of cardiac arrest
and randomised to either ICD therapy or antiarrhythmic
drug therapy, showing a mortality reduction of 23% in the
ICD group [6]. It should be noted that the AVID trial was
the only trial to demonstrate significant survival benefit
from ICD therapy, and according to critical reviews, this
significance was even overestimated due to the threefold
higher use of β-blockers in the ICD arm [7].
Nonsignificant results in the CIDS trial might be due to
the early termination of the study after the data of the AVID
were published. Even so, a similar trend to the AVID trial
was observed. For the CASH trial, the smaller size of the
study might explain the nonsignificance since the observed
relative and absolute risk reductions were similar to the
AVID and CIDS trials. A meta-analysis of these three trials
provided more insight and demonstrated a significant 28%
reduction in all-cause mortality in the ICD-treated group
[8]. Eventually, the results of the AVID trial, the trend in
the CIDS and the meta-analysis led to the acceptance of
ICD therapy for the secondary prevention of sudden
arrhythmic death [3].
Primary Prevention Trials
Since the survival rate of an episode of cardiac arrest is at
best only 8%, the impact of secondary prevention ICD
therapy on population mortality will be low [9]. Therefore,
focus shifted from secondary prevention to the identifica-
tion of patients at risk of life-threatening VAs without a
prior arrhythmic event. Large randomised trials tested the
hypothesis that ICD treatment was beneficial in selected
patients, prior to cardiac arrest or sustained VT (primary
prevention; Table 2). The first primary prevention trial was
the Multicenter Automatic Defibrillator Implantation Trial
(MADIT), which enrolled patients with a prior myocardial
infarction, left ventricular ejection fraction (LVEF) less than
35%, documented nonsustained VT and inducible, non-
suppressible VT on electrophysiological study. Patients
Trials AVID [4] CIDS [5] CASH [6]
Sample size 1016 659 288
Design ICD vs antiarrhythmic drugs ICD vs amiodarone ICD vs amiodarone
vs metoprolol
Patients Resuscitated from near-fatal
VF or post-cardioversion
from sustained VT






Follow-up (months) 18 36 57
Primary endpoint All-cause mortality All-cause mortality All-cause mortality
Results
Risk reduction with ICD 28% (P=0.02) 20% (P=0.14) 23% (P=0.08)
Table 1 Clinical features and












Neth Heart J (2011) 19:24–30 25were randomised to receive either amiodarone therapy or an
ICD, and after the inclusion of 196 patients and with
27 months follow-up, the study demonstrated a 54%
reduction in mortality in the ICD group [10]. Despite these
findings, controversy about the study design remains. There
was no registry of screened patients as in AVID, a high
percentage discontinued taking amiodarone and the ICD-
treated population showed a disproportionately higher use
of β-blockers. The prevailing consensus was that more data
were needed to support the MADIT findings. Therefore, the
results of this study were not adopted in the guidelines until
the results of the Multicenter Unsustained Tachycardia Trial
(MUSTT) were published [11]. MUSTT enrolled patients
with coronary artery disease, LVEF less than 40%,
documented nonsustained VT and inducible, nonsuppres-
sible VTon electrophysiological study, and the survival rate
was comparable with MADIT. Further analysis of the
survival benefit in the MADIT showed that the highest
benefit was observed in patients with an LVEF of less than
26% [12]. These and other observations from the MADIT
trial resulted in a simplified design and a new study. The
MADIT II trial randomised patients with a history of
myocardial infarction and an LVEF less than 30% to either
ICD therapy or no ICD without the requirement of
additional electrophysiological testing and reported a 31%
reduction for mortality in patients treated with an ICD [13].
A meta-analysis of ten primary prevention trials demon-
strated a significant 25% reduction in all-cause mortality in
the ICD-treated patients [14]. Consequently, these findings
led to the inclusion of primary prevention ICD treatment in
the current guidelines [3].
It is worth mentioning that due to the trial designs, left
ventricular dysfunction has developed into the key deter-
minant for the selection of prophylactic ICD implantation
[15]. However, there are several limitations to this criterion.
First of all, accurate measurement of LVEF appeared to be
difficult resulting from different levels of experience and
nonreproducibility [16]. Furthermore, community-wide
registries have demonstrated that a significant group of
nonsurvivors of sudden cardiac death had LVEF >40%
prior to the event and would therefore never be eligible for
prophylactic ICD implantation [9]. Finally, only 35% of the
patients eligible for primary prevention ICD treatment
receive appropriate therapy during long-term follow-up
[13]. Considering these limitations, more accurate risk
markers for the prediction of sudden cardiac death are
needed to improve patient selection criteria for prophylactic
ICD implantation.
Cardiac Resynchronisation Therapy Defibrillator
Congestive heart failure (CHF) is associated with decreased
haemodynamic function, exercise tolerance and quality of
life due to poor left ventricular systolic or diastolic
function. Furthermore, patients with CHF are at increased
risk for sudden cardiac death. As already discussed, ICD
treatment in CHF patients resulted in improved outcome
and a reduction in all-cause mortality [17]. In a significant
number of patients, left ventricular failure is associated with
conduction disturbances causing mechanical dyssynchrony.
Ventricular dyssynchrony further contributes to the already
impaired left ventricular function. Electrical cardiac
resynchronisation therapy (CRT) is a technique which
corrects dyssynchrony caused by ventricular dilatation and
electrical disturbance. In recent years, numerous rando-
mised and observational studies have demonstrated that
CRT may improve functional status, quality of life and may
even lower mortality [18]. It was therefore a logical step to
combine CRT with ICD therapy (CRT-D). The first CRT
implantations in the Netherlands were performed in Utrecht
by thoracic surgeon Dr. Bakker and her team. In 1994,
Cazeau et al. were the first to report on the benefit from
CRT in CHF patients. This study tested the safety and
Table 2 Clinical features and results of four primary prevention ICD trials
Trials MADIT [10] MUSTT [11] MADIT II [13] SCD-HeFT [28]
Sample size 196 704 1232 2521
Design ICD vs antiarrhythmic
drugs as conventional
therapy
EP-guided therapy vs placebo ICD vs optimal
pharmacological
therapy
ICD vs optimal pharmacological
therapy vs optimal pharmacological
therapy + amiodarone






Prior MI, EF≤0.30 Ischaemic and nonischaemic
cardiomyopathy, EF≤0.35
Follow-up (months) 27 39 20 46
Results
Risk reduction with ICD 54% (P=0.001) 51% (P=0.001) 31% (P=0.02) 23% (P=0.007)
EP electrophysiology, EPS electrophysiology study, ICD implantable cardioverter defibrillator, MADIT Multicenter Automatic Defibrillator
Implantation Trial, MI myocardial infarction, EF ejection fraction, MUSTT Multicenter Unsustained Tachycardia Trial, nsVT nonsustained
ventricular tachycardia, SCD-HeFT Sudden Cardiac Death in Heart Failure Trial, VT ventricular tachycardia, AAD antiarrhythmic drugs
26 Neth Heart J (2011) 19:24–30efficacy of multisite pacing in patients with heart failure.
Significant improvements in exercise tolerance, New York
Heart Association (NYHA) class and quality of life were
noted. In 2003, the COMPANION trial was the first to
randomise between optimal medical therapy, optimal
medical therapy and CRT and optimal medical therapy
and CRT-D. CRT-D reduced mortality by 36% in compar-
ison with standard therapy, whereas CRT alone resulted in a
20% reduction in mortality [17]. Other studies (CARE-HF)
demonstrated that CRT alone had the same effect on
mortality as CRT-D in the COMPANION trial. Recently,
the Multicenter Automatic Defibrillator Implantation
Trial–Cardiac Resynchronization Therapy (MADIT-
CRT) enrolled patients with NYHA class I or II, QRS
duration ≥130 ms and LVEF ≤30%. Patients were
randomised to ICD therapy alone or to ICD therapy
with CRT. The primary endpoint was a composite of all-
cause mortality and nonfatal heart failure, and during
follow-up, 17% in the CRT-D group and 25% in the ICD
group reached the primary endpoint. It was concluded
that the incidence of all-cause mortality and nonfatal
heart failure was significantly reduced when CRT was
added to ICD therapy [18].
The Device
The first ICD was large and heavy, could not be
programmed, used epicardial patch electrodes and required
a thoracotomy for the implantation of the epicardial lead
system. ICD implantation procedures were major surgical
interventions, associated with significant morbidity and
mortality. Fortunately, since then, many improvements have
been made. Current devices are relatively small, can be
implanted subcutaneously in the majority of cases and are
connected to an endocardial lead system (Figs. 1 and 2).
Components and Function
An ICD contains a battery, a capacitor to store and deliver
charges, a microprocessor and integrated circuits for
electrogram sensing, data capture, storage and control of
therapy delivery, a header to connect the endocardial leads
used for sensing, pacing and defibrillation (Fig. 3). All
these components together are called a pulse generator and
are encased in a titanium can. The collaboration of these
components results in the essential features of ICD
function, including sensing, detecting and classification of
tachyarrhythmias, delivering therapy (ventricular defibrilla-
tion or antitachycardia pacing (ATP)), monitoring heart
rhythm after therapy and storage of episodes. In this
process, the sensing function determines the depolarisation
sequences of each atrial and ventricular depolarisation and
the detecting function classifies the rhythm by an algorithm
and determines if therapy should be delivered [19].
The device implanted in the 1980s, called the automatic
implantable cardiac defibrillator, was designed only to
recognise and terminate VF by delivering a high-energy
shock [2]. These early devices could not detect unstable
VTs which could degenerate into VF, and because these
devices lacked programmability, separate pacemakers were
required to allow backup bradycardia pacing, leading to
dangerous interactions [19]. Development of second-
generation devices facilitated bradycardia pacing capabili-
ties and were (minimally) programmable. Especially the
bradycardia pacing capability was important as it ended the
need for separate pacemakers. Additionally, these devices
had a limited telemetry function used to test battery strength
Fig. 1 Example of abdominal




Neth Heart J (2011) 19:24–30 27and simply note the number of delivered shocks. For this
telemetry function, an external monitoring device was
needed. In the next decade, many improvements were made,
and in the early 1990s, the first third-generation devices were
introduced. In these devices, ATP was introduced as well as
low-energy shocks for terminating VTs, extensive program-
mability and telemetry functions [20]. Current devices can be
programmed into three or even four different cycle length-
related zones, and different schemes of ATP, shock or a
combination of both can be programmed.
Battery and Capacitor
First-generation devices contained cylindrical aluminium
electrolyticcapacitorsandsilvervanadiumpentoxide batteries
for rapid charge time and the delivery of high-voltage shocks
[21]. Nowadays, lithium-silver vanadium manganese oxide
batteries are used, which resulted in an increase of the service
life of an ICD. Some models use two batteries connected in
series to minimise charge time, thereby improving patient
safety. However, this reduction in charge time is
accompanied with an undesirable increase in ICD size,
since the sizes of the battery and capacitor are the major
determinants of the size of the ICD. Therefore, it is
important to develop capacitors which require a mini-
mum of stored energy but still deliver enough energy for
defibrillation without affecting the ICD service life [22].
Leads
The large first-generation devices were implanted abdom-
inally and needed a thoracotomy to place the lead system.
The lead system used contained a spring patch and apical
cup. The second-generation devices eliminated thoracoto-
my by the introduction of transvenous leads in 1988. With
the introduction of these transvenous leads, the implanta-
tion procedure was transformed from open chest surgery to
a procedure performed in the electrophysiology laboratory
[23]. Further research evaluated the safety and efficacy of
transvenous ICD implantation performed entirely by
electrophysiologists and demonstrated a high success
rate, low complication occurrence and short implantation
time and made subcutaneous ICD implantation in the
electrophysiology laboratory the method of choice.
Besides improvements in the implantation procedures,
improvements were made in the construction of the leads.
Two different kinds of leads are implanted, the coaxial lead
design (Fig. 4, left) in the first- and second-generation
devices and the multilumen lead design (Fig. 4,r i g h t )i n
third-generation devices [24]. The coaxial lead has a layered
design composed of a tip conductor, ring conductor and
defibrillation conductor and an insulation layer between each
conductor. The multilumen lead construction is based on
parallel running conductors through a single insulating body.
Tip and ring conductors are used for pacing and sensing, a
defibrillation conductor for the coil located in the right
ventricle and a defibrillation conductor for the coil located in
the superior vena cava. The insulating body contains extra
Fig. 2 Example of pectoral




Fig. 3 Exploded view of an ICD. ICD implantable cardioverter
defibrillator. Image provided by Biotronik
28 Neth Heart J (2011) 19:24–30lumens to increase the lead’s resistance to compression forces.
The major advantage of multilumen over coaxial leads is the
factthatmoreconductorswillfitintooverallsmallerleads[24].
Despite improvements in the construction of leads, lead
failure occurs frequently. Due to the different design and
materials which are used, longevity ofcurrent implanted leads
may differ significantly [25]. Borleffs et al. evaluated the
survival and failure rate in a large number of defibrillation
leads implanted over a 16-year period [26]. The implanted
leads were produced by different manufacturers, and
different lead diameters were used. Borleffs et al. demon-
strated major differences in failure rates among different
groups and showed an overall 10-year lead survival rate of
73%. Based on these findings, it is important to carefully
select the type of leads which are used for each patient and to
optimise future lead performance [26].
Longevity
Since the first implantation in 1980, worldwide implantation
rates have increased, and therefore, the number of ICD
replacements is expected to increase dramatically. Most of
the replacements are due to end of service life (battery
depletion), and every implantation or replacement brings a
substantial risk of complications. The major determinant of
ICD longevity is the capacitor and therefore the ICD size.
Hauser compared thecumulative survival of ICD patients with
ICD longevity. The probability of a patient living 4, 5 and
6 years after implantation was 79%, 75% and 68%, respec-
tively. Furthermore, the study suggested that if an ICD had ten
service years, the majority of patients would not need a
replacement [27]. Afeasiblesolutionistoproduce larger pulse
generatorswithbatterieswithlongerservicelife.However,this
will impact patients’ acceptance and possibly cause more
pocket-related problems due to the larger volume of the
devices. Furthermore, because of the fast development of new
ICD features, it will sometimes be questionable if it is really
desirable to implant devices with a projected longevity of ten
ormoreyears.Replacementofthecurrentlyusedlithium-silver
vanadium oxide batteries with large-capacity batteries can
increase service life by 2.3 years [27]. These large-capacity
batteries increase the size and weight of the device and are in
conflict with downsizing the device as the market forces.
Algorithms and Rhythm Discrimination
First-generation devices were designed to detect VF only by
waveform analyses. The standard waveform analysis used to
identify cardiac rhythm was the rate of R waves. Due to the
limitations of waveform analyses only, inappropriate therapy
occurred frequently, since episodes of supraventricular tachy-
cardia with fast ventricular response could be classified as VT
or VF and cause inappropriate shocks. The first detection
criterioninallcurrentdevicesisthesignalraterecordedbythe
right ventricular lead. In order to confirm a ventricular
tachyarrhythmia, a specified number of sensed events must
occur at a higher rate than the cutoff rate.
To improve specificity in discriminating between VT or
supraventricular tachycardia, various algorithms have been
developed. As mentioned previously, current ICDs can be
programmedintothreedifferentcyclelength-relatedzonesand
the discriminative detection algorithms can be programmed
in the two lowest zones. The highest programmable zone is
meant for detection of fast VT or VF without any further
discrimination to avoid unnecessary therapy delivery delay.
Single chamber devices use algorithms to discriminate
rhythms, comparing the morphology of the arrhythmia with
the morphology of baseline sinus rhythm, the rate of onset of
arrhythmia and rhythm regularity. Dual-chamber devices can
use additional information retrieved from the atrial lead for
discriminating between rhythms.
All currently available algorithms have some known
limitations such as false-positive and false-negative therapy
deliverydecisions,butbycombiningsomeofthesealgorithms,
the amount of inappropriate inhibition or therapy delivery can
be further reduced. The complexity and combination of
algorithms which can be used depends on power requirements
of the ICD. Since downsizing the ICD is an important goal,
larger batteries which can provide the power requirements for
complex algorithms are not used. These constraints reduce the
use of more complex algorithms, and despite advances in
algorithms, inappropriate therapy still occurs.
Conclusions
Since the introduction of ICD therapy 25 years ago, many
device improvements have been made in size and weight
reduction, arrhythmia discrimination, battery technologies,
shock waveforms, monitoring capabilities and new defibrilla-
Fig. 4 Cross section of coaxial lead construction of a single coil
defibrillation lead with true bipolar sensing and pacing (left) and cross
section of multilumen lead construction (right). Image provided by
Medtronic
Neth Heart J (2011) 19:24–30 29tor electrodes, which have led to wider use and greater patient
acceptance. In the beginning of ICD therapy, patients had to
survive a life-threatening VA to be eligible for ICD treatment,
but due to minimal survival rates, focus shifted to the
identification of patients at high risk. Over the years, many
secondary and primary trials have been executed, and the
findings led to evolving guidelines for ICD implantation. The
ICDiscurrentlyregardedaseverydaytherapyforlargepatient
groups worldwide. Although the beneficial effects of ICD
therapy are clearly proven in a selected population, ongoing
advances in ICD technology and patient selection are
necessary to improve device longevity, lead survival and to
minimise the occurrence of adverse events.
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